TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

HONGENE BIOTECH

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: MistaEscritório: US

Snapshot rápido

HONGENE BIOTECH

ST13

US500000098544404

Classe

1, 5

Pedido

98544404

Registro

8244538

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

25

Atualização mais recente

05/05/2026

Classificação

Registrada

Tipo de marca

Mista

Classes Nice

1, 5

Data de depósito

10/05/2024

Data de registro

05/05/2026

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

05/05/2026

Última transação

05/05/2026

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Fundamento do pedido

Intent to use

Primeiro uso

22/04/2024

Primeiro uso no comércio

22/04/2024

Código do desenho

3

Tipo de titular

03

Localização do titular

Shanghai, CN

Examinador

SOBRAL, CHRISTINA

Unidade examinadora

L90

Localização atual

PUBLICATION AND ISSUE SECTION

Descrição da marca

The mark consists of the stylized stacked words HONGENE BIOTECH to the left of which is a triangular shape comprised of the letters HG.

Titulares e representantes

Titulares

S. C. (pessoa física)

Representantes

Michael T. Smith Birch Stewart Kolasch & Birch LLP

Classificação técnica

Classes Nice

Classe 1Classe 5

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 1

adjuvants, other than for medical or veterinary purposes; bases in the nature of alkalies being chemical preparations; biochemical catalysts; biological preparations for use in industry and science, other than for medical or veterinary purposes; carbonic hydrates; biochemical catalysts; chemical preparations for scientific purposes, other than for medical or veterinary use; chemical reagents, other than for medical or veterinary purposes; chemical substances for analyses in laboratories, other than for medical or veterinary purposes; chemical preparations for analyses in laboratories, other than for medical or veterinary purposes; diagnostic preparations for research laboratory use; diagnostic preparations, other than for medical or veterinary purposes; enzyme preparations for industrial purposes; enzymes for industrial purposes; ferments for chemical purposes, namely, fermentation extract; glucose for industrial purposes, namely, glucosides; industrial chemicals; isotopes for industrial purposes preparations of microorganisms, other than for medical and veterinary use; salts being chemical preparations; sulfides

Classe 5

biological preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease for medical purposes; biological preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease for veterinary purposes; capsules sold empty for medicines; chemical preparations for medical purposes for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease; chemical preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease for pharmaceutical purposes; chemical preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease for veterinary purposes; chemical reagents for medical or veterinary purposes; chemico-pharmaceutical preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease; diagnostic biomarker reagents for medical purposes; diagnostic preparations for medical purposes; diagnostic preparations for medical purposes used by medical laboratories; diagnostic preparations for veterinary purposes; drugs being pharmaceutical preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease for medical purposes; enzyme preparations for medical purposes; enzyme preparations for veterinary purposes; enzymes for medical purposes; enzymes for veterinary purposes; ferments for pharmaceutical purposes; immunostimulants; isotopes for medical purposes; medical preparations for slimming purposes; medicinal hair growth preparations; medicines for treatment and prevention of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss for human purposes; medicines for veterinary purposes for treatment and prevention of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss; pharmaceutical preparations for treatment and prevention cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss; pharmaceuticals for treatment and prevention of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss; phosphates for pharmaceutical purposes for treatment and prevention of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss; preparations of microorganisms for medical or veterinary use; vaccines; veterinary preparations for treatment and prevention of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss

Publicações

Histórico de despachos e eventos da marca no USPTO.

25 publicações encontradas

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

05/05/2026

R.PR

REGISTERED-PRINCIPAL REGISTER

05/05/2026

SUNA

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

15/04/2026

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

15/04/2026

SUPC

STATEMENT OF USE PROCESSING COMPLETE

14/04/2026

IUAF

USE AMENDMENT FILED

06/11/2025

EISU

TEAS STATEMENT OF USE RECEIVED

06/11/2025

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

13/05/2025

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

13/05/2025

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

13/05/2025

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

06/05/2025

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

11/03/2025

PUBO

PUBLISHED FOR OPPOSITION

11/03/2025

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

05/03/2025

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

14/02/2025

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

13/02/2025

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

13/02/2025

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

13/02/2025

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

25/11/2024

GNRT

NON-FINAL ACTION E-MAILED

25/11/2024

CNRT

NON-FINAL ACTION WRITTEN

25/11/2024

DOCK

ASSIGNED TO EXAMINER

25/11/2024

MDSC

NOTICE OF DESIGN SEARCH CODE E-MAILED

10/11/2024

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

10/11/2024

NWAP

NEW APPLICATION ENTERED

10/05/2024

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace HONGENE BIOTECH ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.